X

Drug Profile

AM 580

Alternative Names: AGN-190293; AM-580

Latest Information Update: 17 Nov 2003

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator W.R. Grace
Developer Mitsubishi Pharma Corporation; Sumitomo Pharmaceuticals
Class Antineoplastics; Benzoic acids; Retinoids; Small molecules
Mechanism of Action Immunostimulants; Protein synthesis inhibitors; Retinoic acid receptor alpha agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

06 Apr 2000 Yoshitomi is now called Welfide Corporation
27 Sep 1999 A preclinical study has been added to the drug interactions section
17 Apr 1997 A preclinical study has been added to the Cancer pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com